Provesica Publishes XEN-D0501 Phase 1 Data

XEN-D0501 is currently being assessed for efficacy in overactive bladder in an international phase 2 clinical study.

UK's biopharmaceutical company Provesica has announced the publication of phase 1 human clinical data on XEN-D0501, the company’s TRPV1 antagonist currently being evaluated in a phase 2 clinical study for the treatment of overactive bladder (OAB).

The phase 1 study, published in the British Journal of Clinical Pharmacology1, demonstrated the drug to be safe and well tolerated at doses up to 5 mg twice daily for 14 days.

The study was conducted over 28 days as a placebo-controlled, double-blind, 14-day crossover design, and used ingestible JonahTM capsules and Vitalsense? monitors to record core body temperature accurately and sensitively over the period of the study. The results of the study confirmed that XEN-D0501 was suitable for further clin